Skip to main content
EPIXdelisted

ESSA Pharma Inc.

Biopharma developer (SEC filing verified)·CEO: David R. Parkinson David

EPIX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for EPIX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

10.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

Cash Runway

77.6 mo

Lead Asset

Next Catalyst

Financial data as of Jun 30, 2025.

Run ESSA Pharma Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available ESSA Pharma Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway10.0

77.6 months

Financial Health10.0

D/E 0.01

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Financials

Governance

925 companies232,681 SEC filings21,417 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.